Migraine Excellence Hub

Excellence Forum

Leaders in the field share expert insights and institutional best practices.

FDA Alerts

FDA Alert

FDA Approves First Treatment for Adult, Pediatric Patients With Rare Inherited Blood Clotting Disorder

02/07/2024

Jessica Ganga

The FDA approved the first treatment for patients with congenital thrombotic thrombocytopenic purpura (cTTP), which is a rare and life-threatening blood clotting disorder that may be fatal if left...

02/07/2024

Research Summaries

Conference Coverage

Conference Coverage

AAN 2026: Post Hoc Interim Analysis Shows Atogepant Weight Loss

04/22/2026

Anthony Calabro, MA

Post hoc subgroup analysis of interim phase 3 data shows weight loss with atogepant in migraine and overweight or obesity.

04/22/2026

Conference Coverage

Conference Coverage

OnabotulinumtoxinA vs Topiramate for Chronic Migraine: Higher Patient Satisfaction Reported in US FORWARD Study

04/20/2026

Ashton L. Stahl

Physicians managing chronic migraine may be interested in new comparative patient-reported data from the FORWARD study, which evaluated treatment satisfaction with onabotulinumtoxinA versus topiramate. In...

04/20/2026

Conference Coverage

Conference Coverage

GLP-1 Receptor Agonists Associated With Lower Healthcare Utilization in Chronic Migraine

04/20/2026

Anthony Calabro, MA

At the 2026 American Academy of Neurology Annual Meeting in Chicago, IL, investigators presented real-world evidence evaluating whether glucagon-like peptide-1 receptor agonists influence healthcare...

04/20/2026

Research Summary

Research Summary

Ultrasound-Guided Nerve Blocks Show Comparable Efficacy in Chronic Resistant Migraine, Added Benefits in Select Patients

03/09/2026

Kate Young

The results from a recent randomized controlled trial showed that ultrasound-guided sphenopalatine ganglion (SPG) and greater occipital nerve blocks are equally effective in reducing headache frequency,...

03/09/2026

Research Summary

Research Summary

Safety, Tolerability of Once-Daily Rimegepant for Episodic Migraine Prevention in US Adults

02/26/2026

Ashton L. Stahl

This phase 4 study assessed the long-term safety and tolerability of once-daily oral rimegepant (75 mg) in adults with episodic migraine to inform clinicians about its preventive treatment profile.

02/26/2026

April 2026

Current Issue

April 2026